InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.710 -0.455 (-39.06%)+
Announcement
Release
3 Nov 2025 9:12AM
Price at Release
$1.165
Full Release
download
Summary
Orthocell Limited announced the successful completion of the first Remplir™ surgical case in Hong Kong and the launch of their flagship nerve repair medical device at the Hong Kong Orthopaedic Association's 45th Annual Congress. This marks a significant milestone in Orthocell’s Asia-Pacific commercialisation strategy, closely following the appointment of MontsMed as the exclusive distributor in Hong Kong. The launch and first surgical case signify the start of clinical use and commercial sales in the region. With Hong Kong serving as a strategic entry point to the Guangdong–Hong Kong–Macao Greater Bay Area, Orthocell aims to drive market penetration through leading hospitals and surgeons, supported by Hong Kong's regulatory approval processes. Orthocell's global commercialisation momentum includes initial surgeries in Singapore and the USA, with anticipated sales in Canada and Thailand. The company remains financially robust, with over A$50 million in cash and no debt, aiming for significant revenue growth in FY26.
Key Points
  • Successful completion of first Remplir™ surgical case in Hong Kong.
  • Launch at Hong Kong Orthopaedic Association's 45th Annual Congress.
  • Appointment of MontsMed as exclusive distributor for Hong Kong.
  • Hong Kong serves as a strategic entry point to Greater Bay Area.
  • Initial surgeries in Singapore and USA; sales expected in Canada and Thailand.
  • Orthocell well-funded with A$50 million and aims for revenue growth in FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.